As of September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A carries a market capitalization of 6.98B, placing it among publicly traded companies globally. Its enterprise value stands at 6.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.98B |
| Enterprise Value | 6.86B |
PharmaResources (Shanghai) Co., Ltd Class A's next confirmed earnings release is scheduled for April 29, 2027.
| Earnings Date | 4/29/2027 |
As of September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A has 181.46M shares outstanding.
| Shares Outstanding | 181.46M |
As of September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A trades at a trailing price-to-earnings ratio of 241.66. The price-to-sales ratio is 9.54, and the price-to-book ratio stands at 6.89.
| PE Ratio | 241.66 |
| PS Ratio | 9.54 |
| PB Ratio | 6.89 |
| P/TBV Ratio | 6.95 |
As of September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A trades at an EV/EBITDA multiple of 258.51 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 9.46 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 258.51 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 6.86B versus a market cap of 6.98B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 9.46 |
| EV / EBITDA | 258.51 |
| EV / EBIT | 258.51 |
As of September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A maintains a current ratio of 3.50, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.22, indicating elevated leverage, while an interest coverage ratio of 3.60 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 3.50 |
| Quick Ratio | 1.74 |
| Debt / Equity | 14.22 |
| Debt / EBITDA | 5.44 |
| Interest Coverage | 3.60 |
These figures cover the twelve months ended September 30, 2026. The company generates approximately 627,485.21 in revenue per employee across its workforce of 1,155.00, a quick read on workforce productivity versus industry peers.
| Revenue Per Employee | 627,485.21 |
| Employee Count | 1,155.00 |
Over the twelve months ended September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A recorded an income tax benefit of -3.58M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 25.02M, leaving 28.60M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | -3.58M |
As of the close on November 17, 2026, PharmaResources (Shanghai) Co., Ltd Class A's stock has gained approximately 16.39% over the past 52 weeks. The 50-day moving average sits at 32.75, while the 200-day moving average is 31.46.
| 52-Week Price Change | 16.39% |
| 50-Day Moving Average | 32.75 |
| 200-Day Moving Average | 31.46 |
Over the twelve months ended September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A generated 724.75M in revenue and converted that into 28.60M in net income, yielding earnings per share of 0.16. EBITDA reached 26.53M, while operating income came in at 43.18M.
| Revenue | 724.75M |
| Gross Profit | 192.73M |
| Operating Income | 43.18M |
| Pretax Income | 25.02M |
| Net Income | 28.60M |
| EBITDA | 26.53M |
| EBIT | 26.53M |
| Earnings Per Share (EPS) | 0.16 |
As of September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A holds 269.46M in cash and equivalents against 144.21M in total debt, resulting in a net debt position of -123.77M. Total book value stands at 1.01B, with working capital of 387.89M providing operational flexibility.
| Cash & Cash Equivalents | 269.46M |
| Total Debt | 144.21M |
| Net Debt | -123.77M |
| Equity (Book Value) | 1.01B |
| Book Value Per Share | 5.59 |
| Working Capital | 387.89M |
These figures cover the twelve months ended September 30, 2026.
| Capital Expenditures | -79.01M |
Over the twelve months ended September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A posted a gross margin of 26.59, reflecting its pricing power and cost economics. The operating margin of 5.96 and net profit margin of 3.95 provide insight into operational efficiency.
| Gross Margin | 26.59 |
| Operating Margin | 5.96 |
| Pretax Margin | 3.45 |
| Profit Margin | 3.95 |
| EBITDA Margin | 3.66 |
Over the twelve months ended September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A paid dividends of 0.28 per share. The dividend payout ratio of 178.96 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.22, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to PharmaResources (Shanghai) Co., Ltd Class A shareholders.
| Dividend Per Share | 0.28 |
| Payout Ratio | 178.96 |
| Shareholder Yield | 1.22 |
PharmaResources (Shanghai) Co., Ltd Class A's most recent stock split took place on July 16, 2026 with a 10:13 split ratio.
| Last Split Date | 7/16/2026 |
| Split Ratio | 10:13 |
As of September 30, 2026, PharmaResources (Shanghai) Co., Ltd Class A has an Altman Z-Score of 16.54, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 16.54 |
Already premium?